Intercept Pharmaceuticals (ICPT)

[osaffer]

While ICPT has started its phase 3 several months before Genfit, ICPT has big difficulties to recruit.

Analysts are starting to think why ICPT is late in its enrollment of patient ?

We know the side effects of OCA, maybe, it must cause trouble to prescriptors to send their patients to use Ocaliva instead of Elafibranor.

Don't forget, OCA has received approbation for PBC but, it s only because there was not any treatment for PBC.

With OCA, we have prurit, increase of bad cholesterol, the increase of cardiovascular problem ...

Also, OCA is focus on Fibrosis, and neither on NASH. Fibrosis is a consequence of NASH ... When you have Fibrosis, you are already in an advanced state of NASH.

While Elafibranor attacks NASH and Fibrosis, reduce bad cholesterol etc ...

If you were sick, what treatment will you choose ?

The enrollment of Genfit seems to be very at time.

My understanding, is that ICPT has abandoned the NASH, to focus on Fibrosis, but, it s just a symptom ...

Many analysts begin to be very sceptical about ICPT... and they are right ...

The enrollment of ICPT is a failure !